Volume | 191,714 |
|
|||||
News | - | ||||||
Day High | 0.7669 | Low High |
|||||
Day Low | 0.72 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Atossa Therapeutics Inc | ATOS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.74 | 0.72 | 0.7669 | 0.7532 | 0.7363 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,181 | 191,714 | $ 0.7407357 | $ 142,009 | - | 0.50 - 1.39 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:57:56 | 10 | $ 0.7668 | USD |
Atossa Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
93.98M | 125.30M | - | 0 | -26.96M | -0.22 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Atossa Therapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATOS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.7337 | 0.77 | 0.71 | 0.7441518 | 255,033 | 0.0331 | 4.51% |
1 Month | 0.6515 | 0.833 | 0.62 | 0.7262894 | 288,545 | 0.1153 | 17.7% |
3 Months | 0.776 | 0.841 | 0.62 | 0.7204226 | 322,662 | -0.0092 | -1.19% |
6 Months | 0.977 | 1.39 | 0.62 | 0.9861133 | 589,287 | -0.2102 | -21.51% |
1 Year | 0.68 | 1.39 | 0.50 | 0.8797974 | 549,863 | 0.0868 | 12.76% |
3 Years | 1.57 | 9.80 | 0.50 | 3.25 | 5,483,028 | -0.8032 | -51.16% |
5 Years | 1.31 | 9.80 | 0.50 | 3.30 | 3,583,779 | -0.5432 | -41.47% |
Atossa Therapeutics Description
Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use. |